Eli Lilly Expands Focus on Cancer Treatments with Loxo Oncology Acquisition

New England Council member Eli Lilly announced this week that it would purchase the pharmaceutical company Loxo Oncology, based in Stamford, CT. This acquisition will allow Eli Lilly to expand its portfolio of treatments to include cancer drugs that target rare forms of the disease.

While Eli Lilly has been known for specializing in treatments for diabetes, in recent years the organization has sought to expand into oncology. This purchase is a major step towards that goal, as Loxo Oncology has been a pioneer in scientific innovation. It has played a key role in the development of precision medicine that targets genomically defined cancers, and Eli Lilly remains committed to continuing that essential work.

The President of Lilly Oncology, Anne White, said, “Lilly Oncology is committed to developing innovative, breakthrough medicines that will make a meaningful difference for people with cancer and help them live longer, healthier lives.”

The New England Council commends Eli Lilly for its success and for its continued efforts in the development of critical cancer treatments.

Read more from CNBC and Eli Lilly.

img_side
mask_sidebar
Recently from the Blog

Biogen Announces Collaborations to Develop Treatments for Neurological Disorders

01/14/2019 | Read Post

University of Rhode Island Examines Impact of House Calls Concerning Nutrition Guidance

01/14/2019 | Read Post

In the News

NEC Elects Five Respected Business Leaders to Board of Directors

10/4/2018 | Read Press Release

NEC to Honor Gen. Joseph F. Dunford Jr., Vertex CEO Dr. Jeffrey Leiden, Veterans’ Advocate Travis Mills, Rep. Niki Tsongas

10/2/2018 | Read Press Release